All participants in the control cohort received standard-of-care therapy for AD, including stable-dose acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) and/or memantine according to clinical indication. The gene discussed is ACHE; the disease is Alzheimer disease.